Sanofi sees continued growth and strong financials despite a pipeline setback. Click for this updated look at SNY stock ...

Shares of French pharmaceutical group Sanofi fell 4% on Monday after it flagged another delay to a U.S. regulatory decision ...

Dupixent For Moderate-To-Severe Asthma Treatment Market Expected To Reach ~$8.1 Billion By 2032. December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 ...

Sanofi flagged a second delay to an FDA decision for its experimental multiple sclerosis drug and reported disappointing ...

RegRegon Pharmaceuticals and Sanofi recently announced that the European Commission approved Dupixent for treating moderate-to-severe chronic spontaneous urticaria in patients aged 12 and above who do ...

This year has been one for the books in medicine. From Ozempic’s expanded role in protecting failing kidneys to long‑acting ...

In 2025, drug approvals widen treatment options for chronic diseases, infections and pain, including Ozempic kidney ...

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

Sanofi’s latest fair value estimate has been nudged down from €106.26 to €105.20 as analysts factor in slightly softer revenue growth assumptions, even as the company’s overall risk profile remains ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...